Why the study?
Does HAVAB-M accurately diagnose acute hepatitis A by detecting IgM anti-HAV?
Does HAVAB-M accurately diagnose acute hepatitis A by detecting IgM anti-HAV?
HAVAB-M is a highly sensitive and specific radioimmunoassay for the early diagnosis of acute hepatitis A.
Answers are grounded in this paper and cite their sources.
May support early IgM-based diagnosis of acute hepatitis A; leaves open prospective validation in diverse cohorts.
A three-step solid-phase radioimmunoassay, HAVAB-M, was developed for use in clinical labs as an aid to diagnosing hepatitis A. Polystyrene beads were coated with anti-human IgM (mu-chain specific) and were incubated successively with serum specimen, HAV, and anti-HAV 125I. HAVAB-M was used to assay sera from patients with hepatitis A and was found to have high sensitivity for the IgM antibody to HAV. The antibody was detectable within a few days of onset of symptoms of hepatitis, and it reached maximum concentrations within one to three weeks. The test was designed so that most patients' sera would become negative approximately three months after onset. HAVAB-M was shown to be specific for IgM antibody, with virtually no detection of IgG anti-HAV. The test showed no interference fro rheumatoid factor and no cross-reactivity with sera from patients with hepatitis B or other infectious diseases.
No takes yet. Share an insight, caveat, or question.
Decker et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: